BMEA (Biomea Fusion) Operating Cash Flow per Share : $-3.13 (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Operating Cash Flow per Share?

Biomea Fusion's operating cash flow per share for the three months ended in Mar. 2025 was $-0.70. Biomea Fusion's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.13.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -30.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -91.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Biomea Fusion's Operating Cash Flow per Share or its related term are showing as below:

BMEA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -161.7 Med: -89.5 Max: -30.8
Current: -30.8

During the past 6 years, Biomea Fusion's highest 3-Year average Operating Cash Flow per Share Growth Rate was -30.80% per year. The lowest was -161.70% per year. And the median was -89.50% per year.

BMEA's 3-Year OCF Growth Rate is ranked worse than
87.05% of 1220 companies
in the Biotechnology industry
Industry Median: 8.9 vs BMEA: -30.80

Biomea Fusion Operating Cash Flow per Share Historical Data

The historical data trend for Biomea Fusion's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Operating Cash Flow per Share Chart

Biomea Fusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.42

-1.49

-2.13

-2.83

-3.32

Biomea Fusion Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.89	-0.91	-0.70	-0.83	-0.70

Competitive Comparison of Biomea Fusion's Operating Cash Flow per Share

For the Biotechnology subindustry, Biomea Fusion's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Biomea Fusion Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Biomea Fusion's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-119.894	/	36.106
	=	-3.32

Biomea Fusion's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-25.667	/	36.627
	=	-0.70

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.13

Biomea Fusion Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomea Fusion Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063

Website

https://www.biomeafusion.com

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Executives

Hitchcock Michael J.m.	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle	officer: Chief Financial Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Juan Pablo Frias	officer: Chief Medical Officer	900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc.	10 percent owner	59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Elizabeth Faust	director	C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann	director, 10 percent owner, officer: President and COO	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler	director, 10 percent owner, officer: CEO	726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc	10 percent owner	726 MAIN STREET, REDWOOD CITY CA 94063